Influenza A Virus, H7N9 Subtype
"Influenza A Virus, H7N9 Subtype" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 7 and neuraminidase 9. This avian origin virus was first identified in humans in 2013.
| Descriptor ID |
D064766
|
| MeSH Number(s) |
B04.820.545.405.400.800
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Influenza A Virus, H7N9 Subtype".
Below are MeSH descriptors whose meaning is more specific than "Influenza A Virus, H7N9 Subtype".
This graph shows the total number of publications written about "Influenza A Virus, H7N9 Subtype" by people in this website by year, and whether "Influenza A Virus, H7N9 Subtype" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Influenza A Virus, H7N9 Subtype" by people in Profiles.
-
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 Jun 14; 78(6):1757-1768.
-
Human neutralizing antibodies target a conserved lateral patch on H7N9 hemagglutinin head. Nat Commun. 2024 May 27; 15(1):4505.
-
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial. J Infect Dis. 2024 Feb 14; 229(2):327-340.
-
mRNA vaccines against respiratory viruses. Curr Opin Infect Dis. 2023 10 01; 36(5):385-393.
-
Human antibody recognition of H7N9 influenza virus HA following natural infection. JCI Insight. 2021 10 08; 6(19).
-
Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65?years and older. Vaccine. 2021 02 22; 39(8):1339-1348.
-
An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine. Hum Vaccin Immunother. 2020 12 01; 16(12):3138-3145.
-
Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. Cell Host Microbe. 2019 12 11; 26(6):729-738.e4.
-
Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice. Cell Host Microbe. 2019 12 11; 26(6):715-728.e8.
-
Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.